ATP allosteric activation of atrial natriuretic factor receptor guanylate cyclase.

Publisher: Published by Blackwell Pub. on behalf of the Federation of European Biochemical Societies Country of Publication: England NLM ID: 101229646 Publication Model: Print Cited Medium: Internet ISSN: 1742-4658 (Electronic) Linking ISSN: 1742464X NLM ISO Abbreviation: FEBS J Subsets: MEDLINE

Original Publication: Oxford, UK : Published by Blackwell Pub. on behalf of the Federation of European Biochemical Societies, c2005-

Adenosine Triphosphate/*metabolism ; Receptors, Atrial Natriuretic Factor/*metabolism; Adenosine Triphosphate/analogs & derivatives ; Adenosine Triphosphate/pharmacology ; Allosteric Regulation ; Amino Acid Sequence ; Binding Sites ; Enzyme Activation ; Molecular Sequence Data ; Protein Binding/genetics ; Protein Conformation ; Protein Structure, Tertiary/genetics ; Receptors, Atrial Natriuretic Factor/chemistry ; Receptors, Atrial Natriuretic Factor/genetics ; Signal Transduction/genetics ; Signal Transduction/physiology

Atrial natriuretic factor receptor guanylate cyclase (ANF-RGC) is the receptor and the signal transducer of two natriuretic peptide hormones: atrial natriuretic factor and brain natriuretic peptide. It is a single transmembrane-spanning protein. It binds these hormones at its extracellular domain and activates its intracellular catalytic domain. This results in the accelerated production of cyclic GMP, a second messenger in controlling blood pressure, cardiac vasculature and fluid secretion. ATP is obligatory for the transduction of this hormonal signal. Two models of ATP action have been proposed. In Model 1, it is a direct allosteric transducer. It binds to the defined regulatory domain (ATP-regulated module) juxtaposed to the C-terminal side of the transmembrane domain of ANF-RGC, induces a cascade of temporal and spatial changes and activates the catalytic module residing at the C-terminus of the cyclase. In Model 2, before ATP can exhibit its allosteric effect, ANF-RGC must first be phosphorylated by an as yet unidentified protein kinase. This initial step is obligatory in atrial natriuretic factor signaling of ANF-RGC. Until now, none of these models has been directly validated because it has not been possible to segregate the allosteric and the phosphorylation effects of ATP in ANF-RGC activation. The present study accomplishes this aim through a novel probe, staurosporine. This unequivocally validates Model 1 and settles the over two-decade long debate on the role of ATP in ANF-RGC signaling. In addition, the present study demonstrates that the mechanisms of allosteric modification of ANF-RGC by staurosporine and adenylyl-imidodiphosphate, a nonhydrolyzable analog of ATP, are almost (or totally) identical.

Arch Biochem Biophys. 1982 Sep;217(2):638-46. (PMID: 6127983)
Biochim Biophys Acta. 1990 Apr 9;1052(1):159-65. (PMID: 1969749)
J Mol Graph. 1996 Feb;14(1):51-5, 29-32. (PMID: 8744573)
Rev Physiol Biochem Pharmacol. 1999;135:1-39. (PMID: 9932479)
Annu Rev Neurosci. 2000;23:417-39. (PMID: 10845070)
Mol Cell Biochem. 2010 Jan;334(1-2):37-51. (PMID: 19941036)
Mol Cell Biochem. 2007 Jul;301(1-2):93-107. (PMID: 17277921)
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13414-9. (PMID: 9391039)
Biochemistry. 2008 Jun 24;47(25):6590-601. (PMID: 18500817)
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7882-6. (PMID: 1679239)
Biochem J. 1992 Mar 1;282 ( Pt 2):533-7. (PMID: 1347681)
Peptides. 2005 Jun;26(6):901-32. (PMID: 15911062)
Science. 1995 Feb 3;267(5198):679-81. (PMID: 7839143)
FEBS Lett. 1991 Apr 9;281(1-2):73-6. (PMID: 1673103)
Nature. 1988 Aug 25;334(6184):708-12. (PMID: 2901039)
J Biol Chem. 2004 Jul 2;279(27):28625-31. (PMID: 15117952)
Mol Cell Biol. 1998 Apr;18(4):2164-72. (PMID: 9528788)
Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14507-12. (PMID: 17724338)
Acta Crystallogr A. 1990 Feb 1;46 ( Pt 2):73-82. (PMID: 2180438)
Can J Physiol Pharmacol. 2001 Aug;79(8):682-91. (PMID: 11558677)
Nature. 1995 Nov 2;378(6552):65-8. (PMID: 7477288)
Biochem Biophys Res Commun. 2006 Aug 4;346(3):840-4. (PMID: 16782058)
Structure. 1997 Dec 15;5(12):1627-37. (PMID: 9438863)
FEBS Lett. 1992 Jan 27;296(3):254-8. (PMID: 1347019)
Biochemistry. 2006 Feb 14;45(6):1899-909. (PMID: 16460036)
FEBS J. 2005 Nov;272(21):5572-83. (PMID: 16262696)
J Investig Med. 2005 Nov;53(7):371-7. (PMID: 16297365)
Eur J Biochem. 1995 Nov 15;234(1):317-22. (PMID: 8529658)
Science. 1987 Mar 6;235(4793):1224-6. (PMID: 2881352)
Mol Cell Biochem. 2001 Jan;217(1-2):165-72. (PMID: 11269661)
J Biol Chem. 2003 Mar 28;278(13):11159-66. (PMID: 12547834)
Peptides. 2005 Jun;26(6):969-84. (PMID: 15911066)
Methods. 1999 Dec;19(4):521-31. (PMID: 10581151)
Mol Cell Biochem. 2009 Apr;324(1-2):39-53. (PMID: 19137266)
Mol Cell Biochem. 2002 Jan;230(1-2):3-30. (PMID: 11952094)
J Biol Chem. 1991 Mar 5;266(7):4088-93. (PMID: 1671858)
J Biol Chem. 1998 Jun 26;273(26):16311-8. (PMID: 9632692)
Biochem Biophys Res Commun. 2008 Mar 7;367(2):440-5. (PMID: 18178149)
Biochem Biophys Res Commun. 2005 Jun 24;332(1):149-56. (PMID: 15896311)
Mol Cell Biochem. 2010 Jan;334(1-2):3-36. (PMID: 19957201)
FEBS Lett. 1987 Jul 27;219(2):375-9. (PMID: 2886366)
J Mol Biol. 1999 Jan 15;285(2):713-25. (PMID: 9878439)
J Biol Chem. 1994 Dec 9;269(49):30741-4. (PMID: 7982997)
FEBS Lett. 2009 Apr 17;583(8):1327-30. (PMID: 19306880)
Science. 1985 Nov 15;230(4727):767-70. (PMID: 2932797)

R01 HL084584 United States HL NHLBI NIH HHS; R01 HL084584-03S1 United States HL NHLBI NIH HHS; HL084584 United States HL NHLBI NIH HHS

8L70Q75FXE (Adenosine Triphosphate)
EC 4.6.1.2 (Receptors, Atrial Natriuretic Factor)
EC 4.6.1.2 (atrial natriuretic factor receptor A)

Date Created: 20100618 Date Completed: 20100707 Latest Revision: 20211020

20240829

PMC2916748

10.1111/j.1742-4658.2010.07670.x

20553491